CAPRICOR THERAPEUTICS, INC. (CAPR) Form 10-Q — May 13, 2026
Capricor Therapeutics, Inc. reported a net loss of $33.9 million for the three months ended March 31, 2026, compared to a net loss of $24.4 million for the same period in 2025. The company's cash and cash equivalents decreased from $287.8 million as of December 31, 2025 to $105.4 million as of March 31, 2026, primarily due to ongoing efforts to prepare for the potential commercialization of its lead product candidate, Deramiocel. Research and development expenses increased by $8.5 million, or 45%, to $27.4 million for the three months ended March 31, 2026, compared to $18.9 million for the same period in 2025.
Key figures
- Eps
- -0.59
- Eps Beat
- 0
- Revenue
- 0
- Guidance
- The company expects to spend approximately $100.0 million to $125.0 million on the Deramiocel program and $7.0 million to $10.0 million on the exosome platform in 2026.
- Net Income
- -33,941,345
- Total Debt
- 6,339,862
- Revenue Yoy
- 0
- Cash Position
- 105,421,484
Price after filing
Close on the filing date to close N calendar days later (from $30.33). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.